Plasma Amino Acid Profiling in Major Depressive Disorder Treated With Selective Serotonin Reuptake Inhibitors

CNS Neuroscience and Therapeutics

Volumn 21, Issue 5, 2015, Pages 417-424

  Woo, Hye In ^a   Chun, Mi Ryung ^b   Yang, Jeong Soo ^b   Lim, Shinn Won ^a   Kim, Min Ji ^b   Kim, Seon Woo ^b   Myung, Woo Jae ^a   Kim, Doh Kwan ^a   Lee, Soo Youn ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

Author keywords

Alpha aminobutyric acid; Ethanolamine; Glutamic acid; Metabolomics; Selective serotonin reuptake inhibitor

Indexed keywords

2 AMINOBUTYRIC ACID; 3 AMINO 2 METHYLPROPIONIC ACID; 4 AMINOBUTYRIC ACID; ALANINE; AMINO ACID; AMINOADIPIC ACID; ANSERINE; ARGININE; ASPARAGINE; ASPARTIC ACID; BETA ALANINE; CARNOSINE; CITRULLINE; CYSTATHIONINE; CYSTINE; ETHANOLAMINE; GLUTAMIC ACID; GLUTAMINE; GLYCINE; HISTIDINE; HOMOCYSTINE; HYDROXYPROLINE; ISOLEUCINE; LEUCINE; METHIONINE; PHOSPHOSERINE; PROLINE; SARCOSINE; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN;

ADULT; AGED; AMINO ACID ANALYSIS; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PSYCHOPHARMACOTHERAPY; TANDEM MASS SPECTROMETRY; BLOOD; BLOOD ANALYSIS; DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINO ACIDS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 84928053899     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12372     Document Type: Article

References (58)

1. Ferrari AJ, Somerville AJ, Baxter AJ, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med 2013;43:471-481.
2. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
3. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008;358:55-68.
4. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36:764-785.
5. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM, National Birth Defects Prevention S. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007;356:2684-2692.
6. Mann JJ. The medical management of depression. N Engl J Med 2005;353:1819-1834.
7. Wong DT, Perry KW, Bymaster FP. Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 2005;4:764-774.
8. Nierenberg AA, Farabaugh AH, Alpert JE, et al. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000;157:1423-1428.
9. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007;62:1217-1227.
10. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
11. Gartlehner G, Hansen RA, Morgan LC, et al. Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review. Rockville, MD: Agency for Healthcare Research and Quality, 2011.
12. Mulder RT, Frampton CM, Luty SE, Joyce PR. Eighteen months of drug treatment for depression: predicting relapse and recovery. J Affect Disord 2009;114:263-270.
13. Dunlop BW, Holland P, Bao W, Ninan PT, Keller MB. Recovery and subsequent recurrence in patients with recurrent major depressive disorder. J Psychiatr Res 2012;46:708-715.
14. Machado-Vieira R, Ibrahim L, Zarate CA Jr. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. CNS Neurosci Ther 2011;17:699-704.
15. Wingenfeld K, Wolf OT. HPA axis alterations in mental disorders: impact on memory and its relevance for therapeutic interventions. CNS Neurosci Ther 2011;17:714-722.
16. Cattaneo A, Gennarelli M, Uher R, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013;38:377-385.
17. Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009;34:173-186.
18. Kaddurah-Daouk R, Weinshilboum RM. Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 2014;95:154-167.
19. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009;35:165-176.
20. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012;58:139-147.
21. Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995;5(SUPPL):71-75.
22. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012;125:2222-2231.
23. Do KQ, Lauer CJ, Schreiber W, et al. gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem 1995;65:2652-2662.
24. Fonteh AN, Harrington RJ, Tsai A, Liao P, Harrington MG. Free amino acid and dipeptide changes in the body fluids from Alzheimer's disease subjects. Amino Acids 2007;32:213-224.
25. Leichtle AB, Nuoffer JM, Ceglarek U, et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012;8:643-653.
26. Xu HB, Fang L, Hu ZC, et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res 2012;200:1054-1057.
27. Ni Y, Su M, Lin J, et al. Metabolic profiling reveals disorder of amino acid metabolism in four brain regions from a rat model of chronic unpredictable mild stress. FEBS Lett 2008;582:2627-2636.
28. Mauri MC, Boscati L, Volonteri LS, et al. Predictive value of amino acids in the treatment of major depression with fluvoxamine. Neuropsychobiology 2001;44:134-138.
29. Palmio J, Huuhka M, Saransaari P, et al. Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Res 2005;137:183-190.
30. Held PK, White L, Pasquali M. Quantitative urine amino acid analysis using liquid chromatography tandem mass spectrometry and aTRAQ reagents. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:2695-2703.
31. Johnson DW. Free amino acid quantification by LC-MS/MS using derivatization generated isotope-labelled standards. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:1345-1352.
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
33. Chiarla C, Giovannini I, Siegel JH. Characterization of alpha-amino-n-butyric acid correlations in sepsis. Transl Res 2011;158:328-333.
34. Yudkoff M, Blazer-Yost B, Cohn R, Segal S. On the clinical significance of the plasma alpha-amino-n-butyric acid:leucine ratio. Am J Clin Nutr 1979;32:282-285.
35. Effros RM. Alpha aminobutyric acid, an alternative measure of hepatic injury in sepsis? Transl Res 2011;158:326-327.
36. Behr GA, Moreira JC, Frey BN. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev 2012;2012:609421.
37. Martins-de-Souza D, Guest PC, Harris LW, et al. Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl Psychiatry 2012;2:e87.
38. Modica-Napolitano JS, Renshaw PF. Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder. Biol Psychiatry 2004;55:273-277.
39. Lykidis A, Wang J, Karim MA, Jackowski S. Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway. J Biol Chem 2001;276:2174-2179.
40. Veiga-da-Cunha M, Hadi F, Balligand T, Stroobant V, Van Schaftingen E. Molecular identification of hydroxylysine kinase and of ammoniophospholyases acting on 5-phosphohydroxy-L-lysine and phosphoethanolamine. J Biol Chem 2012;287:7246-7255.
41. Kim S, Choi KH, Baykiz AF, Gershenfeld HK. Suicide candidate genes associated with bipolar disorder and schizophrenia: an exploratory gene expression profiling analysis of post-mortem prefrontal cortex. BMC Genom 2007;8:413.
42. Sugden C. One-carbon metabolism in psychiatric illness. Nutr Res Rev 2006;19:117-136.
43. Anglin RE, Garside SL, Tarnopolsky MA, Mazurek MF, Rosebush PI. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J Clin Psychiatry 2012;73:506-512.
44. Marazziti D, Baroni S, Picchetti M, et al. Mitochondrial alterations and neuropsychiatric disorders. Curr Med Chem 2011;18:4715-4721.
45. Lopresti AL, Hood SD, Drummond PD. A review of lifestyle factors that contribute to important pathways associated with major depression: diet, sleep and exercise. J Affect Disord 2013;148:12-27.
46. Zubenko GS, Hughes HB 3rd, Jordan RM, Lyons-Weiler J, Cohen BM. Differential hippocampal gene expression and pathway analysis in an etiology-based mouse model of major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2014;165B:457-466.
47. Gardner A, Boles RG. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:730-743.
48. Mauri MC, Ferrara A, Boscati L, et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998;37:124-129.
49. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1155-1158.
50. Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 2002;7(SUPPL 1):S71-S80.
51. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2014;10:1-12.
52. Serafini G, Pompili M, Innamorati M, Dwivedi Y, Brahmachari G, Girardi P. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression. Curr Pharm Des 2013;19:1898-1922.
53. Wang SJ, Su CF, Kuo YH. Fluoxetine depresses glutamate exocytosis in the rat cerebrocortical nerve terminals (synaptosomes) via inhibition of P/Q-type Ca2 + channels. Synapse 2003;48:170-177.
54. Schipke CG, Heuser I, Peters O. Antidepressants act on glial cells: SSRIs and serotonin elicit astrocyte calcium signaling in the mouse prefrontal cortex. J Psychiatr Res 2011;45:242-248.
55. Maes M, Galecki P, Chang YS, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:676-692.
56. Karege F, Widmer J, Bovier P, Gaillard JM. Platelet serotonin and plasma tryptophan in depressed patients: effect of drug treatment and clinical outcome. Neuropsychopharmacology 1994;10:207-214.
57. Urbina M, Pineda S, Piñango L, Carreira I, Lima L. [3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine. Int J Immunopharmacol 1999;21:631-646.
58. Zoga M, Oulis P, Chatzipanagiotou S, et al. Indoleamine 2, 3-dioxygenase and immune changes under antidepressive treatment in major depression in females. In Vivo 2014;28:633-638.